Edesa Biotech Inc - Asset Resilience Ratio
Edesa Biotech Inc (EDSA) has an Asset Resilience Ratio of -3.43% as of September 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2018)
This chart shows how Edesa Biotech Inc's Asset Resilience Ratio has changed over time. Check Edesa Biotech Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Edesa Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Edesa Biotech Inc (EDSA) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $-500.00K | -3.43% |
| Total Liquid Assets | $-500.00K | -3.43% |
Asset Resilience Insights
- Limited Liquidity: Edesa Biotech Inc maintains only -3.43% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Edesa Biotech Inc Industry Peers by Asset Resilience Ratio
Compare Edesa Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Edesa Biotech Inc (2014–2018)
The table below shows the annual Asset Resilience Ratio data for Edesa Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-09-30 | 51.60% | $6.08 Million | $11.78 Million | +25.76pp |
| 2017-09-30 | 25.83% | $1.99 Million | $7.72 Million | -5.00pp |
| 2016-09-30 | 30.83% | $3.99 Million | $12.94 Million | -17.46pp |
| 2015-09-30 | 48.29% | $5.02 Million | $10.39 Million | +45.12pp |
| 2014-09-30 | 3.16% | $458.10K | $14.47 Million | -- |
About Edesa Biotech Inc
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-… Read more